Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00817063 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
A Phase 3 study of Eczema, sponsored by Stiefel, a GSK Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 599
- Enrollment target
- 20
- Study locations
NCT00817063: Completed Phase 3 study of Eczema, sponsored by Stiefel, a GSK Company.
NCT00817063 is a Phase 3 study of Eczema that has completed, run by Stiefel, a GSK Company. The registered enrollment target is 599 participants, above the 186-participant average among 29 other Eczema trials with a reported enrollment target (222% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00817063, a Phase 3 study of Eczema, has completed, sponsored by Stiefel, a GSK Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 599 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
Primary Outcome
The investigator assigned PGA grades according to a 5-point scale (clear \[not detectable\], almost clear \[less than 10% of affected hand surface\], mild disease \[less than 10% of affected hand surface\], moderate disease \[10% to 30% of affected hand surface\], severe disease \[\>30% of affected hand surface\]). PGA ratings were based on an integrated clinical picture of signs, symptoms, and the extent of disease. Symptoms included erythema, scaling, hyperkeratosis/lichenification, vesiculati
Conditions Studied
Interventions
- DRUG Placebo
- DRUG alitretinoin
Study Locations (20)
California
- Shahram Jacobs, MD, Inc. - Encino
- University of California, San Diego Dermatology Clinical Trials Unit - La Jolla
- Dermatology Research Associates - Los Angeles
- Laser and Dermatology Center - Marina del Rey
- Integrated Research Group - Riverside
- University of California, Davis - Sacramento
- Therapeutics Clinical Research - San Diego
- East Bay Psoriasis Treatment Center - San Ramon
- Stanford University Dept of Dermatology - Stanford
- Solano Clinical Research, Dow Pharmaceutical Sciences - Vallejo
Arkansas
- Johnson Dermatology - Fort Smith
- Dermatology Research of Arkansas - Little Rock
- Hull Dermatology - Rogers
Colorado
- Longmont Clinic, P.C. - Longmont
- Western State Clinical Research Inc. - Wheat Ridge
Florida
- Park Avenue Dermatology, PA - Orange Park
- Palm Beach Research Center - West Palm Beach
Alabama
- University of Alabama, Birmingham - Birmingham
Arizona
- Radiant Research Inc. - Tucson
District of Columbia
- George Washington University - Medical Faculty Associates - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 599 participants |
| Start Date | 2009-01-08 |
| Est. Completion | 2012-04-26 |
| Phase | Phase 3 |
What the finished NCT00817063 record still lists
NCT00817063 is an interventional study that assigns participants to a tested intervention. The registered 599 participants enrollment target is mid-sized for trials with a published cap, above the 186-participant average among 29 other Eczema trials with a reported enrollment target (222% higher).
The record links to 1 condition, with Eczema appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00817063 names 20 study sites across 7 states, led by California, Arkansas, Colorado.
Frequently Asked Questions
What is clinical trial NCT00817063 about?
NCT00817063 is a clinical study titled "Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema". The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
What is the current status of trial NCT00817063?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 599 participants. The study started on 2009-01-08. Estimated completion is 2012-04-26.
What conditions does trial NCT00817063 study?
This clinical trial studies the following conditions: Eczema.
What interventions are being tested in trial NCT00817063?
The interventions under investigation include: Placebo (DRUG), alitretinoin (DRUG).
Who is sponsoring clinical trial NCT00817063?
This trial is sponsored by Stiefel, a GSK Company, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00817063 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eczema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00817063's enrollment target sits among peer trials
599 2nd of 29 the highest of 29 other Eczema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eczema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
RECRUITING · Phase 3
-
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Flourish: Exploring the Early Infant Gut Microbiome
RECRUITING · NA
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
Monitoring Pregnancy and Infant Outcomes Following Tralokinumab Exposure During Pregnancy in the US and Canada - PROTECT
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI